These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36863753)

  • 1. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
    van der Togt CJT; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36863753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Smolen JS; Landewé RBM; Bergstra SA; Kerschbaumer A; Sepriano A; Aletaha D; Caporali R; Edwards CJ; Hyrich KL; Pope JE; de Souza S; Stamm TA; Takeuchi T; Verschueren P; Winthrop KL; Balsa A; Bathon JM; Buch MH; Burmester GR; Buttgereit F; Cardiel MH; Chatzidionysiou K; Codreanu C; Cutolo M; den Broeder AA; El Aoufy K; Finckh A; Fonseca JE; Gottenberg JE; Haavardsholm EA; Iagnocco A; Lauper K; Li Z; McInnes IB; Mysler EF; Nash P; Poor G; Ristic GG; Rivellese F; Rubbert-Roth A; Schulze-Koops H; Stoilov N; Strangfeld A; van der Helm-van Mil A; van Duuren E; Vliet Vlieland TPM; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):3-18. PubMed ID: 36357155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
    Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
    Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PMJ; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Pchelnikova P; Blaas E; Senolt L; Szekanecz Z; Choy EH; Dougados M; Jacobs JW; Geenen R; Bijlsma JW; Zink A; Aletaha D; Schoneveld L; van Riel P; Dumas S; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2022 Jan; 81(1):20-33. PubMed ID: 34407926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
    Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
    Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S; Nikiphorou E; Sepriano A; Ortolan A; Webers C; Baraliakos X; Landewé RBM; Van den Bosch FE; Boteva B; Bremander A; Carron P; Ciurea A; van Gaalen FA; Géher P; Gensler L; Hermann J; de Hooge M; Husakova M; Kiltz U; López-Medina C; Machado PM; Marzo-Ortega H; Molto A; Navarro-Compán V; Nissen MJ; Pimentel-Santos FM; Poddubnyy D; Proft F; Rudwaleit M; Telkman M; Zhao SS; Ziade N; van der Heijde D
    Ann Rheum Dis; 2023 Jan; 82(1):19-34. PubMed ID: 36270658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs.
    Momen Majumder MS; Hasan ATMT; Choudhury MR; Ahmed S; Miah MT; Amin MR; Shahin MA; Islam A; Shazzad MN; Hassan MM; Ahmedullah AK; Rahman MM; Yesmeen S; Uddin T; Haq SA
    Cureus; 2024 Apr; 16(4):e59395. PubMed ID: 38707172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L; Humphries B; Rutherford M; Taieb V; Willems D; Tillett W
    Arthritis Res Ther; 2024 Feb; 26(1):50. PubMed ID: 38360699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
    Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
    Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EULAR definition of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PM; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Blaas E; Senolt L; Szekanecz Z; Choy E; Dougados M; Jacobs JW; Geenen R; Bijlsma HW; Zink A; Aletaha D; Schoneveld L; van Riel P; Gutermann L; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2021 Jan; 80(1):31-35. PubMed ID: 33004335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JWJ; Burmester GR; de Wit M; Falzon L; Landewé R
    Ann Rheum Dis; 2020 Jun; 79(6):744-759. PubMed ID: 32033937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
    Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
    BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.